Use of Evolocumab in Familial Hyperlipidemia With Isolated Heart Transplant

• DOI: 10.1016/j.jaccas.2024.102426
• Publication Date: 2024-08-07T18:37:59Z
• Authors: Colin Mackenzie; McHale Anderson; Kevin S. Shah
• Keywords: Evolocumab; Hyperlipidemia; PCSK9; Proprotein Convertases; Kexin

We describe a novel use of evolocumab for successful postoperative lipid control in patient with familial hyperlipidemia who underwent isolated heart transplantation. believe that this case carries valuable lessons regarding post-transplant proprotein convertase subtilisin kexin 9 inhibitor implications the future combined organ allocation and transplantation waitlist times.